JP2016513963A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513963A5 JP2016513963A5 JP2015561833A JP2015561833A JP2016513963A5 JP 2016513963 A5 JP2016513963 A5 JP 2016513963A5 JP 2015561833 A JP2015561833 A JP 2015561833A JP 2015561833 A JP2015561833 A JP 2015561833A JP 2016513963 A5 JP2016513963 A5 JP 2016513963A5
- Authority
- JP
- Japan
- Prior art keywords
- poxvirus vector
- ara
- subject
- vector according
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000017060 Arachis glabrata Nutrition 0.000 claims 11
- 241001553178 Arachis glabrata Species 0.000 claims 11
- 235000010777 Arachis hypogaea Nutrition 0.000 claims 11
- 235000018262 Arachis monticola Nutrition 0.000 claims 11
- 239000013566 allergen Substances 0.000 claims 11
- 235000020232 peanut Nutrition 0.000 claims 11
- 108020001507 fusion proteins Proteins 0.000 claims 10
- 102000037865 fusion proteins Human genes 0.000 claims 10
- 210000004698 lymphocyte Anatomy 0.000 claims 10
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 238000012258 culturing Methods 0.000 claims 4
- 150000007523 nucleic acids Chemical group 0.000 claims 4
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims 3
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims 3
- 230000015556 catabolic process Effects 0.000 claims 3
- 238000006731 degradation reaction Methods 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 2
- 102000044159 Ubiquitin Human genes 0.000 claims 2
- 108090000848 Ubiquitin Proteins 0.000 claims 2
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000178 monomer Substances 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 208000007089 vaccinia Diseases 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 102100037935 Polyubiquitin-C Human genes 0.000 claims 1
- 108010056354 Ubiquitin C Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 238000000586 desensitisation Methods 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000010039 intracellular degradation Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361852239P | 2013-03-15 | 2013-03-15 | |
| US61/852,239 | 2013-03-15 | ||
| PCT/AU2014/000286 WO2014138824A1 (en) | 2013-03-15 | 2014-03-17 | Immune modulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019059511A Division JP2019134707A (ja) | 2013-03-15 | 2019-03-26 | 免疫調節 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513963A JP2016513963A (ja) | 2016-05-19 |
| JP2016513963A5 true JP2016513963A5 (enExample) | 2017-05-18 |
| JP6549042B2 JP6549042B2 (ja) | 2019-07-24 |
Family
ID=51535630
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561833A Active JP6549042B2 (ja) | 2013-03-15 | 2014-03-17 | 免疫調節 |
| JP2019059511A Pending JP2019134707A (ja) | 2013-03-15 | 2019-03-26 | 免疫調節 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019059511A Pending JP2019134707A (ja) | 2013-03-15 | 2019-03-26 | 免疫調節 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11173206B2 (enExample) |
| EP (2) | EP3685853A1 (enExample) |
| JP (2) | JP6549042B2 (enExample) |
| KR (2) | KR102125594B1 (enExample) |
| CN (2) | CN105163756A (enExample) |
| AU (1) | AU2014231734B2 (enExample) |
| CA (1) | CA2906735C (enExample) |
| DK (1) | DK2968528T3 (enExample) |
| ES (1) | ES2909750T3 (enExample) |
| HK (1) | HK1219436A1 (enExample) |
| IL (1) | IL241596B (enExample) |
| MY (1) | MY193724A (enExample) |
| NZ (1) | NZ630642A (enExample) |
| RU (2) | RU2709771C2 (enExample) |
| SG (1) | SG11201507657QA (enExample) |
| WO (1) | WO2014138824A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2914286T3 (da) | 2012-10-30 | 2021-11-08 | Aravax Pty Ltd | Hidtil ukendte immunterapeutiske molekyler og anvendelser deraf |
| RU2709771C2 (ru) | 2013-03-15 | 2019-12-19 | Симентис Лимитед | Иммунная модуляция |
| KR20160075532A (ko) | 2013-09-25 | 2016-06-29 | 아라백스 피티와이 엘티디 | 신규한 면역치료제 조성물 및 이의 용도 |
| CA3265584A1 (en) | 2016-08-19 | 2025-03-14 | Sementis Ltd | VIRUS VACCINES |
| IL304904A (en) * | 2021-02-01 | 2023-10-01 | St Phi Therapeutics Co Ltd | Target protein degradation system and its use |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6037135A (en) | 1992-08-07 | 2000-03-14 | Epimmune Inc. | Methods for making HLA binding peptides and their uses |
| US5773705A (en) | 1992-12-31 | 1998-06-30 | Wisconsin Alumni Research Foundation | Ubiquitin fusion protein system for protein production in plants |
| WO2001040264A2 (en) * | 1999-12-06 | 2001-06-07 | Panacea Pharmaceuticals, Llc. | Peptide antigens |
| US8623379B2 (en) | 2000-03-02 | 2014-01-07 | Emory University | Compositions and methods for generating an immune response |
| US7265208B2 (en) * | 2001-05-01 | 2007-09-04 | The Regents Of The University Of California | Fusion molecules and treatment of IgE-mediated allergic diseases |
| EP2253709B1 (en) * | 2002-05-16 | 2018-04-11 | Bavarian Nordic A/S | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome |
| CA2527102A1 (en) * | 2003-07-10 | 2005-01-20 | Cytos Biotechnology Ag | Packaged virus-like particles |
| CN101001872A (zh) * | 2004-04-16 | 2007-07-18 | 宏观基因有限公司 | FcγRIIB－特异性抗体及其使用方法 |
| CN100374152C (zh) * | 2005-12-23 | 2008-03-12 | 中国农业大学 | 一种过敏性反应抑制剂 |
| EP1835031A1 (en) | 2006-03-14 | 2007-09-19 | Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe | Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans |
| EP2153841B2 (en) * | 2008-08-15 | 2015-11-11 | Circassia Limited | Vaccine comprising Amb a 1 peptides for use in the treatment of ragweed allergy |
| GB201104537D0 (en) * | 2011-03-17 | 2011-05-04 | Cambridge Entpr Ltd | Treatment for peanut allergy |
| RU2709771C2 (ru) * | 2013-03-15 | 2019-12-19 | Симентис Лимитед | Иммунная модуляция |
-
2014
- 2014-03-17 RU RU2018121086A patent/RU2709771C2/ru active
- 2014-03-17 JP JP2015561833A patent/JP6549042B2/ja active Active
- 2014-03-17 KR KR1020157029396A patent/KR102125594B1/ko active Active
- 2014-03-17 MY MYPI2015703226A patent/MY193724A/en unknown
- 2014-03-17 ES ES14763738T patent/ES2909750T3/es active Active
- 2014-03-17 RU RU2015144308A patent/RU2662927C2/ru active
- 2014-03-17 KR KR1020197033558A patent/KR102212253B1/ko active Active
- 2014-03-17 CN CN201480024524.2A patent/CN105163756A/zh active Pending
- 2014-03-17 CN CN201811364128.0A patent/CN109517842A/zh active Pending
- 2014-03-17 EP EP20156953.0A patent/EP3685853A1/en not_active Withdrawn
- 2014-03-17 US US14/777,457 patent/US11173206B2/en active Active
- 2014-03-17 EP EP14763738.3A patent/EP2968528B1/en active Active
- 2014-03-17 CA CA2906735A patent/CA2906735C/en active Active
- 2014-03-17 AU AU2014231734A patent/AU2014231734B2/en active Active
- 2014-03-17 DK DK14763738.3T patent/DK2968528T3/da active
- 2014-03-17 SG SG11201507657QA patent/SG11201507657QA/en unknown
- 2014-03-17 NZ NZ630642A patent/NZ630642A/en unknown
- 2014-03-17 WO PCT/AU2014/000286 patent/WO2014138824A1/en not_active Ceased
- 2014-03-17 HK HK16107611.6A patent/HK1219436A1/zh unknown
-
2015
- 2015-09-16 IL IL241596A patent/IL241596B/en active IP Right Grant
-
2019
- 2019-03-26 JP JP2019059511A patent/JP2019134707A/ja active Pending
-
2021
- 2021-10-14 US US17/501,305 patent/US20220088189A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cepika et al. | Tregopathies: monogenic diseases resulting in regulatory T-cell deficiency | |
| JP7285279B2 (ja) | 新生物ワクチン用製剤 | |
| Xu et al. | Use of a liver-targeting immune-tolerogenic mRNA lipid nanoparticle platform to treat peanut-induced anaphylaxis by single-and multiple-epitope nucleotide sequence delivery | |
| Ottenhoff et al. | Vaccines against tuberculosis: where are we and where do we need to go? | |
| ES2869155T3 (es) | Péptidos inmunogénicos para su uso en la prevención y/o tratamiento de enfermedades infecciosas, enfermedades autoinmunitarias, respuestas inmunitarias a alofactores, enfermedades alérgicas, tumores, rechazo de injerto y respuestas inmunitarias contra vectores virales usados para terapia génica o vacunación génica | |
| McKinstry et al. | Regulation of CD4+ T‐cell contraction during pathogen challenge | |
| Nel et al. | Nano-enabled COVID-19 vaccines: meeting the challenges of durable antibody plus cellular immunity and immune escape | |
| JP2016513963A5 (enExample) | ||
| GB2463586A (en) | li-Key/Antigenic Epitope Hybrid Peptide Vaccines | |
| JP2014523406A5 (enExample) | ||
| JP2017521064A5 (enExample) | ||
| Nolz et al. | Strategies and implications for prime-boost vaccination to generate memory CD8 T cells | |
| WO2018026914A1 (en) | Transfection of dendritic cells and methods therefor | |
| JP2019508044A5 (enExample) | ||
| Hoft et al. | Optimizing vaccine development | |
| CN101724023B (zh) | 结核分枝杆菌抗原限制性表位肽 | |
| RU2015144308A (ru) | Иммунная модуляция | |
| Giese | Introduction to molecular vaccinology | |
| ES2689141T3 (es) | Modulación de inmunogenicidad antigénica mediante la adición de epítopos reconocidos por linfocitos T citolíticos naturales | |
| JP2009536036A5 (enExample) | ||
| Iurescia et al. | Strategies for improving DNA vaccine performance | |
| Weiss et al. | Allergens are not pathogens: why immunization against allergy differs from vaccination against infectious diseases | |
| Dzul-Rosado et al. | Immunogenicity of OmpA and OmpB antigens from Rickettsia rickettsii on mononuclear cells from Rickettsia positive Mexican patients | |
| EP2696891A1 (en) | New vaccines for prevention and treatment of tuberculosis | |
| Chaitra et al. | HLA‐A* 0201‐restricted Cytotoxic T‐cell Epitopes in Three PE/PPE Family Proteins of Mycobacterium tuberculosis |